ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: 2500 • ACR Convergence 2025

    Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review

    Emily Glowienka1, Sarah Nickolls2, Kevin Coady1, Eesha Kodi3, Ian Steinfield1, Florence Wilson3, Alicia N. Pepper3, Svetlana I. Nihtyanova4, Roger A. Levy5 and Daniel Moldaver6, 1Precision AQ, Boston, MA, 2GSK, Research & Development, Stevenage, United Kingdom, 3Precision AQ, Vancouver, BC, Canada, 4GSK, Clinical Sciences, Research & Development, London, United Kingdom, 5GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, 6GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada

    Background/Purpose: SSc is a rare autoimmune connective tissue disorder; up to 64% of patients with SSc develop interstitial lung disease (ILD), which can result in…
  • Abstract Number: 2474 • ACR Convergence 2025

    Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected

    Carlos Valera Ribera1, JUAN JOSE ALEGRE SANCHO2, Ivan Castellvi3, Marta Ibañez4 and Javier Narváez5, 1Hospital Universitario Doctor Peset, València, Spain, 2Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, 3Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, 4Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 5Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: Anticentromere antibody (ACA)-positive interstitial lung disease (ILD) in systemic sclerosis (SSc) is traditionally considered less aggressive than anti-topoisomerase I (ATA)-positive ILD. However, its clinical…
  • Abstract Number: 1864 • ACR Convergence 2025

    Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis

    Giulio Forte1, Vasiliki Liakouli1, Alessia Salzillo2, Mario Angeli3, Daniele Mauro1, Antonio Ciancio1, Barbara De Marino2, Iacopo Panarese1, Mario Faenza1, roberto giacomelli4, Andreas Ramming5 and Francesco Ciccia6, 1Università della Campania Luigi Vanvitelli, Naples, Italy, 2University of Campania L. Vanvitelli, Naples, Italy, 3Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 4Università Campus Bio-Medico, Roma, Italy, 5Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, 6Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by type I interferon (IFN-I) production and mitochondrial dysfunction. Emerging evidence suggests that activation of the…
  • Abstract Number: 1573 • ACR Convergence 2025

    Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival

    Katherine van der Wouden1, Georgy Gomon2, Rachel Knevel2, Michel Tsang-A-Sjoe3, Alexandre Voskuijl3 and Jeska de Vries-Bouwstra2, 1Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Amsterdam University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Patients with systemic sclerosis (SSc) face an uncertain long‑term outlook; understanding how their health‑related quality of life (HRQoL) changes over time can help them…
  • Abstract Number: 1161 • ACR Convergence 2025

    Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases

    Javier Narváez1, Orfa Barrios2, Pol Maymó-Paituvi3, JUAN JOSE ALEGRE SANCHO4, Ivan Castellví5, Vanesa Vicens Zygmunt6, Guadalupe Bermudo7, Laia De Daniel Bisbe3, Martí Aguilar-Coll8, Montserrat Roig Kim3, Joan Miquel Nolla3 and Maria Molina-Molina7, 1Hospital Universitario de Bellvitge, Barcelona, Spain, 2Department of Rheumatology. Hospital Nacional Arzobispo Loayza, Lima, Peru, 3Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 4Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, 6Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, 7Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, 8Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: To evaluate the efficacy, safety, and tolerability of the antifibrotic agents nintedanib and pirfenidone in the treatment of interstitial lung disease (ILD) associated with…
  • Abstract Number: 0961 • ACR Convergence 2025

    Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis

    Cuong Tran-Manh1, Thuong Trinh-Minh2, Christoph Liebel3 and Jörg Distler4, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Nordrhein-Westfalen, Germany, 2Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 4University Hospital Duesseldorf and HHU, Duesseldorf, Germany

    Background/Purpose: Retinoic acid-related orphan receptor-α (RORα) is a nuclear transcription factor implicated in immune regulation, circadian rhythm, and metabolism. However, its role in fibrotic diseases…
  • Abstract Number: 0688 • ACR Convergence 2025

    Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study

    Benjamin Chaigne1, Alexandre bense2, Frédérique Aubourg3, Christian AGARD4, Yannick Allanore5, Alice berezne1, Gregory Pugnet6, Eric Hachulla7, Vincent Cottin8, Arnaud Hot8, bertrand Dunogue1, Anuxcy Kanagaratnam2, Sylvain Palat9, Alain Lescoat10, Sabine berthier11, Emmanuel Chatelus12, Sébastien Rivière13, David Launay14, Marie-Elise Truchetet15, Anh-Tuan Dinh-Xuan3 and Luc Mouthon1, 1Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 2AP HP, Paris, France, 3Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5Université Paris Cité, Paris, France, 6CHU, Montpelliers, France, 7CHU, Lilles, France, 8CHU, Lyon, France, 9Limoges, Limoges, France, 10CHU Rennes - University Rennes, Rennes, France, 11CHU, Dijon, France, 12Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, 13AP HP, Parsi, France, 14Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 15Bordeaux University Hospital, Bordeaux, France

    Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
  • Abstract Number: 0884 • ACR Convergence 2025

    Risk Score for Early Mortality to stratify for Intensive SSc Therapy

    Ann-Christin Pecher1, Boubaya Marouane2, Oliver Distler3, Vanessa Smith4, Jeska de Vries-Bouwstra5, Radim Bečvář6, Gianluca Moroncini7, David Launay8, Yannick Allanore9, Maria De Santis10, Kamal Solanki11, Carlomaurizio Montecucco12, Luca Idolazzi13, Nihal Fathi14, Przemyslaw Kotyla15, Muriel Elhai16 and Jörg Henes17, 1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Unit of Clinical Research, Paris Seine Saint Denis University, Bobigny, France, Paris, France, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 4Ghent University Hospital, Gent, Belgium, 5Leiden University Medical Center, Leiden, Netherlands, 6Department of Internal Medicine, Charles University,, Prague, Czech Republic, 7Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, 8Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille France, Lille, France, 9Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, 10Humanitas University, Pieve Emanuele, Italy, 11Waikato Hospital, Hamilton, New Zealand, 12Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, Pavia, Italy, 13Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy, Verona, Italy, 14Department of Rheumatology ,Rehabilitation & physical medicine, Assiut University Hospital, Assiut, Egypt, Assiut, Egypt, 15Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland, 16University Hospital zurich, Zürich, Switzerland, 17Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany

    Background/Purpose: Systemic sclerosis (SSc) is a rare disease that often leads to severe complications and premature mortality. Recent advancements in the field have led to…
  • Abstract Number: 0032 • ACR Convergence 2025

    Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease

    Kumar Thurimella1, Ahmed Mohamed2, Chenhao Li3, Tommi Vatanen4, Daniel Graham3, Roisin Owens5, Sabina Leanti La Rosa6, Damian Plichta3, Sergio Bacallado5 and Ramnik Xavier7, 1University of Colorado School of Medicine, Aurora, CO, 2Broad Institute, Boston, 3Broad Institute, Cambridge, MA, 4University of Helsinki, Helsinki, Finland, 5University of Cambridge, Cambridge, United Kingdom, 6NMBU, As, Norway, 7Harvard Medical School, Boston, MA

    Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…
  • Abstract Number: 2498 • ACR Convergence 2025

    Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease

    Poulami Dey1, Rachael Bogle2, Qinmengge Li3, Olesya Plazyo4, Rosemary Gedert4, Carleigh Zahn4, Pei-Suen Tsou4, John Varga4, Lam Tsoi4, Johann Gudjonsson4 and Dinesh Khanna4, 1Michigan Medicine, Ann Arbor, MI, 2University of Michigan, Holland, OH, 3University of Michigan, Ypsilanti, MI, 4University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is characterized by skin fibrosis, dysregulated immune response, and vascular system dysfunction. Interstitial lung disease (ILD) is one of the leading…
  • Abstract Number: 2473 • ACR Convergence 2025

    Nailfold Capillaroscopy Improves Cardiovascular Risk Stratification in Systemic Sclerosis: An Adjustment to the SCORE2 Algorithm

    Carlos Valera Ribera1, Javier Narváez2, Joaquin Lacasa Molina3, Adrián Mayo-Juanatey4, Paula Mencio5, Patricia Leon Torralba5, Pablo Andujar Brazal5, Ignacio Vázquez Gómez6 and JUAN JOSE ALEGRE SANCHO7, 1Hospital Universitario Doctor Peset, València, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario Doctor Peset, Valencia, Spain, 4Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, 5Hospital Universitario Doctor Peset, València, Comunidad Valenciana, Spain, 6H.U. Doctor Peset, Valencia, 7Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain

    Background/Purpose: Systemic sclerosis (SSc) is associated with both micro- and macrovascular damage, increasing cardiovascular (CV) risk. The SCORE2 algorithm estimates CV event risk in the…
  • Abstract Number: 1863 • ACR Convergence 2025

    Bag3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis

    Claudia Iannone1, Margot De Marco2, Antonina Minniti3, Giuseppe Armentaro4, Antonia Falco2, Angela D'Ardia2, paola Manzo2, Liberato Marzullo5, Anna Basile2, Alessandra Rosati2, Maria Caterina Turco2, Roberto Caporali6 and Nicoletta Del Papa7, 1University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, 2Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy, Baronissi, Campania, Italy, 3ASST Gaetano Pini, milano, Milan, Italy, 4ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, 5Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy, Baronissi, Italy, 6University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, 7ASST Pini CTO, Milano, Milan, Italy

    Background/Purpose: BAG3 (Bcl2-associated athanogene 3) regulates cellular pathways including apoptosis and autophagy, and induces fibroblast-to-myofibroblast transformation. In systemic sclerosis (SSc), myofibroblasts drive fibrosis of skin…
  • Abstract Number: 1571 • ACR Convergence 2025

    Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling

    Ifeoluwa Emmanuel Bamigbola1, Jayakumar Vadakekolathu1, Stefano Di Donato2, Vishal Kakkar3, Rebecca Ross4, Yasser El-Sherbiny1 and Francesco Del Galdo3, 11Nottingham Trent University, Department of Biosciences, School of Science and Technology, Nottingham, United Kingdom, 2University of Leeds, Canosa Sannita, Chieti, Italy, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: The skin from patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS) already exhibits fibrotic alterations such as collagen deposition and perivascular infiltration (1),…
  • Abstract Number: 1079 • ACR Convergence 2025

    Sociodemographic, Clinical, and Community-Level Deprivation Factors are Associated with Health-Related Quality of Life in Systemic Sclerosis

    Sarah Smith1, Paula Ramos2, Dulaney Wilson3, Diane Kamen4 and Richard Silver1, 1Medical University of South Carolina, Charleston, SC, 2Emory University School of Medicine, Atlanta, GA, 3Medical University of South Carolina, Charleston, 4Medical University of South Carolina, Johns Island, SC

    Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease with heterogeneous manifestations and significant impairment in health-related quality of life (HRQoL). SSc outcomes are shaped…
  • Abstract Number: 0959 • ACR Convergence 2025

    Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score

    Bich Na Choi1, Claudia Pedroza2, Brian Skaug3, Maureen Mayes4 and Shervin Assassi5, 1UTHealth Houston Institute for Clinical Research & Learning Health Care, Houston, TX, 2UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4UT Health Houston Division of Rheumatology, Houston, TX, 5Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX

    Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…
  • 1
  • 2
  • 3
  • …
  • 56
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology